Business Medical Dialogues
    • facebook
    • twitter
    Sign in Signup
    • facebook
    • twitter
    Sign in Signup
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    Sign InRegister
    Business Medical Dialogues
    Sign inRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • Diabetes Treatment:...

    Diabetes Treatment: CDSCO expert panel marketing authorization Nod to Glenmark's SGLT2 Inhibitor Remogliflozin etabonate

    Meghna A SinghaniaBy Meghna A SinghaniaPublished On 2019-03-31T13:39:18+05:30  |  Updated On 2021-08-16T14:06:02+05:30

    New Delhi: Mumbai-based Glenmark Pharmaceuticals Limited recently received the permission from the IND Committee of the Central Drugs Standard Control Organisation (CDSCO) to manufacture and market Remogliflozin etabonate(RE) tablets of 100mg strength. The product is indicated for the treatment of Type 2 Diabetes Mellitus (T2DM) as monotherapy and in addition to the existing anti-diabetic therapies.


    The decision to this effect was taken up in the recent committee meeting held on 15th March 2019. The IND committee is headed by Dr Balram Bharagava, Director General ICMR.


    The decision was given after the company submitted the results of statistical analysis of data after completion of 612 subjects of Phase III clinical study along with Pharmacokinetic study reports and requested for permission to manufacture and market the product in the country.


    As per the proposal submitted, SGLT2 inhibitors are novel anti-diabetic drugs that help achieve glycemic control by acting on the SGLT2 receptors in the proximal tubule of the kidney, thereby preventing renal reabsorption of glucose and promoting excretion of glucose in the urine.


    Prior to this, Glenmark had conducted various clinical trials for the product. Remogliflozin has been evaluated in 26 clinical studies (phases I, II and III). These studies provide information about the safety, efficacy, pharmacokinetics, pharmacodynamics, drug interaction and evaluation in special populations of Remogliflozin etabonate.


    The committee after going through the clincial trial summary observed that the results of phase III clinical trial in Indian subjects with type 2 diabetes, confirm the efficacy and safety of Remogliflozin 100 mg and Remogliflozin 250 mg and non-inferiority with dapagliflozin 10 mg.


    Based on all the efficacy and safety data, Remogliflozin etabonate is expected to be an important, effective and safe SGLT2 inhibitor for use in Indian subjects with type 2 Diabetes Mellitus.




    In light of the recommendation of the IND committee meeting dated 03.12.2018, the firm presented their proposal along with results of the Phase III clinical trial data of first 612 subjects. The committee noted that in the Phase III clinical trial results, there is no much variation in terms of efficacy between Remogliflozin etabonate tablets 100 mg and 250 mg. After detailed deliberation, based on detailed non-clinical and clinical data (Phase I,II,III) generated, the committee recommended for grant of permission to manufacture and market Remogliflozin etabonate tablets of 100mg strength for the treatment of Type 2 Diabetes Mellitus (T2DM) as monotherapy and in addition to the existing anti-diabetic therapies subject to the following conditions:-




    • The firm should submit protocol for active Post Marketing Surveillance of the drug to CDSCO before launching the product in the market.

    • Proposed Package Insert, Label, Carton to be adopted should be got approved from CDSCO as per the requirements of the Rules.



    Also Read: Glenmark gets USFDA nod for generic version of acne treatment gel

    blood sugar CDSCO Central Drugs Standard Control Organisation Clinical Trial diabetes diabetes drug diabetes manageent drug safety efficacy Glenmark Glenmark Pharmaceuticals Glenmark RE health health news Healthcare IND Committee inhibitor medicines pharma news pharma news india RE Remogliflozin etabonate SGLT2 SGLT2 Inhibitor SGLT2 inhibitors sugar type-2 diabetes 

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Meghna A Singhania
    Meghna A Singhania

      Meghna A Singhania is the founder and Editor-in-Chief at Medical Dialogues. An Economics graduate from Delhi University and a post graduate from London School of Economics and Political Science, her key research interest lies in health economics, and policy making in health and medical sector in the country. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      Johnson & Johnson Risperdal Lawsuit: US Court Slashes USD 8 Billion Verdict

      Johnson & Johnson Risperdal Lawsuit: US Court Slashes USD 8 Billion Verdict

      Covid-19 Impact: NPPA asks drugmakers to submit availablility data of 58 APIs, details

      Covid-19 Impact: NPPA asks drugmakers to submit availablility data of 58 APIs, details

      Delhi HC directs cashless service to all hospitals: GIPSA stayed on Ophthalmological Society petition

      Delhi HC directs cashless service to all hospitals: GIPSA stayed on Ophthalmological Society...

      Rising prices of hydroxychloroquine raw material forces small scale pharmas in Haridwar to stop production

      Rising prices of hydroxychloroquine raw material forces small scale pharmas in Haridwar to stop...

      Pharmaceuticals safe in PET packaging: High-level committee

      Pharmaceuticals safe in PET packaging: High-level committee

      Union Pharma Secretary Holds video conference with Pharma manufacturers and associations, takes feedback

      Union Pharma Secretary Holds video conference with Pharma manufacturers and associations, takes...

      NPPA fixes prices of 29 formulations under DPCO, check out details

      NPPA fixes prices of 29 formulations under DPCO, check out details

      Top priority on Delivery of Medicines through Speed Post: Minister

      Top priority on Delivery of Medicines through Speed Post: Minister

      View All

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 29 March 2022 11:15 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier

      This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
      verify here.

      Search only trustworthy HONcode health websites:

      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2020 Minerva Medical Treatment Pvt Ltd

      © 2020 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok
      X
      X